Clinical Trials in Minneapolis

Showing 3021-3040 of 6,957 trials

N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers

NCT00967005

The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological gamblers (PG) symptoms in nicotine dependent pathological gamblers.

GamblingTobacco Use Disorder

University of Chicago28 participantsStarted Sep 2009

New Haven, Connecticut, United States • Minneapolis, Minnesota, United States

COMPLETEDPhase 1< 1 mile

Safety and Pharmacokinetics of HU6

NCT05433506

Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Twelve subjects will be randomized (1:1) to treatment sequence to determine the order in which they will receive the tablet or capsule formulation in Period 1 and Period 2. Part 2 is an open-label study of up to 4 single, ascending dose levels of HU6 administered as the tablet formulation. Eight subjects will be enrolled to participate in all of the ascending study periods.

Obese

Rivus Pharmaceuticals, Inc.30 participantsStarted Sep 2022

Minneapolis, Minnesota, United States

COMPLETEDNA< 1 mile

Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation

NCT03775512

Prospective, non-randomized, pre-market clinical evaluation of the QDOT MICRO™ Catheter to demonstrate the safety and effectiveness when compared to an historical control performance goal.

Paroxysmal Atrial Fibrillation

Biosense Webster, Inc.283 participantsStarted Jan 2019

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Atlantis, Florida, United States +19 more locations

N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers

Safety and Pharmacokinetics of HU6

Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation

Find Trials by Condition in Minneapolis

Evaluation of 19-gauge vs 21-gauge EBUS TBNA in Assessing Thoracic Lymphadenopathy

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

Single-Stage Integra Reconstruction in Burns

Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

OPTIMIZE IDE for the Treatment of ACS

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

A Study to Test if TEV-48574 is Effective in Relieving Asthma

Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma

Personalized Medicine for Canadians With Hemophilia

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

The TREFOIL Concept 5 Year Clinical Investigation